CpG‐based nanovaccines bolster ovarian cancer immunotherapy via the Gbp2‐Pin1‐NFkB pathway‐mediated reprogramming of tumor‐associated macrophages (TAMs). The gene discussed is PIN1; the disease is neoplasm.